Pfizer Inc. (NYSE:PFE) Shares Sold by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,985 shares of the biopharmaceutical company’s stock after selling 2,620 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Pfizer were worth $1,216,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Geode Capital Management LLC raised its stake in Pfizer by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares during the period. Norges Bank purchased a new position in shares of Pfizer in the 4th quarter valued at $2,328,986,000. Massachusetts Financial Services Co. MA raised its stake in shares of Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Pfizer by 7.7% in the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock valued at $1,548,889,000 after acquiring an additional 4,167,222 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.5%

NYSE PFE opened at $25.45 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company’s 50 day simple moving average is $23.67 and its 200 day simple moving average is $24.84. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a market capitalization of $144.66 billion, a P/E ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the business earned $0.82 earnings per share. The firm’s revenue was down 7.8% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.76%. Pfizer’s dividend payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PFE shares. Wolfe Research raised their target price on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research note on Wednesday, April 30th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group lifted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Redburn Atlantic dropped their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 30th. Finally, Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.